Data Insights

BI-836858 by Boehringer Ingelheim International for Refractory Acute Myeloid Leukemia: Likelihood of Approval

BI-836858 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Refractory Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - BI-836858 in Refractory Acute Myeloid Leukemia

Data Insights

BI-836858 by Boehringer Ingelheim International for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

BI-836858 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - BI-836858 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Empagliflozin by Boehringer Ingelheim International for Pulmonary Arterial Hypertension: Likelihood of Approval

Empagliflozin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Pulmonary Arterial Hypertension. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Empagliflozin in Pulmonary Arterial Hypertension

Data Insights

Zongertinib by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval

Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Zongertinib in Non-Small Cell Lung Cancer

Data Insights

Survodutide by Boehringer Ingelheim International for Liver Fibrosis: Likelihood of Approval

Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Liver Fibrosis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Survodutide in Liver Fibrosis

Data Insights

Survodutide by Boehringer Ingelheim International for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According...

Likelihood of Approval and Phase Transition Success Rate Model - Survodutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Data Insights

BI-3706674 by Boehringer Ingelheim International for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

BI-3706674 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction....

Likelihood of Approval and Phase Transition Success Rate Model - BI-3706674 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

BI-3706674 by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval

BI-3706674 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-3706674 in Esophageal Cancer

Data Insights

BI-3706674 by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval

BI-3706674 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-3706674 in Gastric Cancer

Data Insights

YH-25724 by Boehringer Ingelheim International for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval

YH-25724 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metabolic Dysfunction-Associated Steatotic Liver Disease...

Likelihood of Approval and Phase Transition Success Rate Model - YH-25724 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Data Insights

Spesolimab by Boehringer Ingelheim International for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval

Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase III for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo...

Likelihood of Approval and Phase Transition Success Rate Model - Spesolimab in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)

Data Insights

Survodutide by Boehringer Ingelheim International for Obesity: Likelihood of Approval

Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Obesity. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Survodutide in Obesity

Data Insights

BI-836880 by Boehringer Ingelheim International for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

BI-836880 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Wet (Neovascular / Exudative) Macular...

Likelihood of Approval and Phase Transition Success Rate Model - BI-836880 in Wet (Neovascular / Exudative) Macular Degeneration

Data Insights

BI-765423 by Boehringer Ingelheim International for Pulmonary Fibrosis: Likelihood of Approval

BI-765423 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Pulmonary Fibrosis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-765423 in Pulmonary Fibrosis

Data Insights

Zongertinib by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval

Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...

Data Insights

Zongertinib by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval

Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Colorectal Cancer. According to GlobalData,...

Data Insights

BI-905711 by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval

BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BI-905711 in Metastatic Colorectal Cancer

Data Insights

BI-905711 by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval

BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-905711 in Esophageal Cancer

Data Insights

BI-905711 by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval

BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-905711 in Gastric Cancer

Data Insights

Zongertinib by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...